Navigation Links
Lung transplants in cystic fibrosis patients with life-threatening bacteria sparks debate at ISHLT
Date:4/11/2008

Boston, MA (April 11, 2008) During Wednesdays Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.

A highlight of the session was the concluding debate: Burkholderia Cenocepacia is an Absolute Contradiction to Transplantation between Duane Davis, MD, Duke University Medical Center, Durham, NC and Redha R. Souilemas, MD, European Georges Pompidou Hospital, Paris.

Cystic Fibrosis, Burkholderia Cenocepacia and Lung Transplantation

Patients with life threatening lung disease due to CF have a lot to gain by lung transplantation. Compared to other possible indications for transplant, patients with CF have, in general, the best outcomes, and a successful transplant can mean a significant increase in lifespan and a huge improvement in quality of life.

A hallmark of advanced CF lung disease is repeated severe chest infections. In most cases these infections are responsive to treatment with powerful antibiotics and their presence does not influence the outcomes after transplant in CF patients.

However in 5 percent of patients with CF, bacteria called Burkholderia cenocepacia infects the lungs before transplant. This infection is very resistant to antibiotics and if it returns after the transplant surgery it is extremely difficult to control and can be life threatening.

It is estimated that less than only 30 percent of patients with Burkholderia cenocepacia who receive lung transplants survive beyond five years with many dying very early after transplant due to recurrence of the severe infection with this bacteria. In comparison, CF patients without this infection can expect 5-year post-transplant survival of up to 70 percent on average. The debate within the transplant community is whether or not to allocate donor lungs to patients with Burkholderia cenocepacia knowing that the success rate is much worse than in CF patients without this infection.

According to Dr. Davis, lung transplants should not be performed on CF patients with Burkholderia cenocepacia until new research indicates a way to achieve better early results by better control of the infection. He went on to say new ways of treating patients with Burkholderia cenocepacia should be examined in clinical trials with a hypothesis, careful data collection and safety monitoring. Only after such research approaches have generated a clinical advance in treatment of this infection should lung transplants in CF patients with Burkholderia cenocepacia be performed in the same manner as those who do not have the disease.

Representing the counter argument, Dr. Souilemas said he believes it is very difficult to choose between two patients who need the same procedure. Medicine is science and art, said Dr. Souilemas in the debate. During his argument, Dr. Souilemas also presented information on reversible factors other than the infection itself, which may contribute to the patients poor health before receiving a lung transplant, and thus contribute to poor outcomes. Dr. Souilemas finished his debate by proposing that each patient be viewed as a potential lung transplant candidate and encouraged clinicians to attempt to transplant each as successfully as possible.

In the end, both physicians agreed that more careful research into transplants in CF patients with Burkholderia cenocepacia would improve success rates for these patients.


'/>"/>

Contact: Lauren Mason
lmason@masonpr.com
210-857-2521
International Society for Heart and Lung Transplantation
Source:Eurekalert

Related medicine news :

1. National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families
2. New Heart Pump Helps Women Awaiting Transplants
3. Blood-incompatible infant heart transplants safe, may save more lives
4. Blood-Incompatible Heart Transplants Safe for Infants
5. Lung Transplants May Not Help Most Cystic Fibrosis Children
6. Alcohol may amplify chronic rejection in lung transplants
7. Bone marrow cell transplants help nerve regeneration
8. Cell Transplants Hold Promise for Heart Attack Survivors
9. UCLA Program Aims to Revolutionize Kidney Transplants
10. Rural Residents Get Fewer Organ Transplants: Study
11. National study will look at German-made heart pump for children needing heart transplants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... LLC to help enterprises move workloads to the cloud. Cirracore provides a ... their cloud without traversing the Internet. Transformation Solutions (TSL Partners) provides a ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... products, announced today the introduction of the newly designed, innovative shoulder wrap. ... better cold therapy coverage for the injured arm and shoulder to promote faster ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Shark Finds and Kevin Harrington, ... DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved some ... play in the wet and early morning dew or right after a rain shower, might ...
(Date:2/8/2016)... ... February 08, 2016 , ... Coast Dental has a ... National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, is hosting a ... Coast Dental , located next to Target at 1207 North Peachtree Parkway in Peachtree ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016 The life of Dr. Jan ... been anything but ordinary.  Twists of fate, combined with sheer ... and the constraints of communist Czechoslovakia to New ... go on to make history by playing a key role ... in the world, Remicade.  Dr. Vilcek brings readers along his ...
(Date:2/9/2016)... 2016  Bluestar Silicones will promote its Silbione® ... long-term implant applications and announce certification of its ... (MD&M) West Conference (Booth #1759), February 9-10, at ... --> Available in 01 through ... outstanding physical properties enabling our customers to optimize ...
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
Breaking Medicine Technology: